Lisanti Capital Growth LLC Grows Position in ARS Pharmaceuticals, Inc. $SPRY

Lisanti Capital Growth LLC lifted its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 87.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 396,509 shares of the company’s stock after buying an additional 185,320 shares during the period. Lisanti Capital Growth LLC owned approximately 0.40% of ARS Pharmaceuticals worth $4,619,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Torren Management LLC purchased a new stake in shares of ARS Pharmaceuticals during the fourth quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of ARS Pharmaceuticals by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after buying an additional 982 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of ARS Pharmaceuticals by 197.5% during the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after buying an additional 4,427 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of ARS Pharmaceuticals during the third quarter valued at $82,000. Finally, Osaic Holdings Inc. boosted its position in shares of ARS Pharmaceuticals by 52.8% during the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after buying an additional 1,803 shares during the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Trading Down 3.5%

Shares of NASDAQ:SPRY opened at $7.94 on Friday. The stock has a market capitalization of $788.44 million, a price-to-earnings ratio of -3.95 and a beta of 0.93. The company has a debt-to-equity ratio of 2.79, a quick ratio of 7.06 and a current ratio of 4.94. The stock’s 50-day simple moving average is $8.18 and its two-hundred day simple moving average is $9.24. ARS Pharmaceuticals, Inc. has a 52-week low of $6.66 and a 52-week high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.08). The firm had revenue of $22.68 million during the quarter, compared to analysts’ expectations of $22.20 million. ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%. Analysts expect that ARS Pharmaceuticals, Inc. will post -1.75 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on SPRY shares. Weiss Ratings cut ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 15th. Northland Securities initiated coverage on ARS Pharmaceuticals in a research report on Thursday, April 9th. They set an “outperform” rating and a $25.00 price objective on the stock. Wall Street Zen raised ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Leerink Partners set a $26.00 target price on ARS Pharmaceuticals and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Finally, Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $28.25.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.